


PHARMACEUTICAL 2017

CTI BIOPHARMA CORP Rank 202 of 313







PHARMACEUTICAL 2017

CTI BIOPHARMA CORP Rank 202 of 313



The relative strengths and weaknesses of CTI BIOPHARMA CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CTI BIOPHARMA CORP compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 226% points. The greatest weakness of CTI BIOPHARMA CORP is the variable Assets, Current, reducing the Economic Capital Ratio by 195% points.

The company's Economic Capital Ratio, given in the ranking table, is -340%, being 76% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	55,824
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	40,646
Liabilities, Non-Current	14,926
Other Assets	4,996
Other Compr. Net Income	1,241
Other Expenses	-3,700
Other Liabilities	514
Other Net Income	-3,791
Property and Equipment	3,023
Research and Development	64,961
Revenues	57,405
Selling, General and Administrative Expense	45,306

Output Variable	Value in 1000 USD
Assets	63,843
Liabilities	56,086
Expenses	106,567
Stockholders Equity	7,757
Net Income	-52,953
Comprehensive Net Income	-52,332
Economic Capital Ratio	-340%